Modeling Glioblastoma with Brain Organoids: New Frontiers in Oncology and Space Research
Authors:
- Laura BeganiLBLaura Begani
- Luigi Gianmaria RemoreLRLuigi Gianmaria Remore
- Stefania RagostaSRStefania Ragosta
- Massimiliano Domenico RizzaroMassimiliano Domenico Rizzaro
- Laura GuarnacciaLGLaura Guarnaccia
- Giovanni Andrea AlottaGAGiovanni Andrea Alotta
- Laura RiboniLRLaura Riboni
- Monica Rosa MiozzoMMMonica Rosa Miozzo
- Emanuela BarillaEBEmanuela Barilla
- Chiara GaudinoCGChiara Gaudino
- Marco LocatelliMLMarco Locatelli
- Emanuele GarziaEGEmanuele Garzia
Open Access
- 1 November 2025
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10664
Abstract
Glioblastoma (GBM) is the most malignant primary brain tumor, characterized by extensive heterogeneity, invasiveness, infiltrating behavior, and resistance to standard therapies, including radiation and temozolomide (TMZ). Despite considerable efforts in investigating its pathophysiology, GBM represents one of the most challenging cancers to treat, with a median survival rate under 15 months and a 5-year survival rate below 5%. A major barrier to progress in GBM therapy development is the lack of reliable preclinical models that faithfully recapitulate the tumor’s molecular heterogeneity, invasive behavior, and complex microenvironment. Traditional cell lines and xenograft models often fail to reflect the key pathological features of human GBM, including immune suppression, vascular abnormalities, and treatment resistance. In recent years, attention has focused on the development of numerous clinically relevant GBM models based on brain organoids as a powerful “disease-in-a-dish” model. They strongly mimic GBM key histopathological and molecular features, such as the tumor’s cellular heterogeneity, genetic landscape, and microenvironment, enabling more accurate studies of tumor biology, invasion, and therapeutic response in a controlled in vitro setting. Notably, research in microgravity offers a unique and promising platform to study cancer biology under conditions that enhance tissue self-organization, mimic aspects of tumor growth, and potentially unveil novel therapeutic vulnerabilities. This review compares organoids to conventional preclinical models, tracing their historical development and salient features, focusing on the preparation and use of organoids in GBM research. We also introduce a novel and promising field of organoid application: space-based organoid brain research.Keywords
Funding Information
- Ministero della Salute (RC2025)
- Ministero della Salute (GR-2019-12370940)
- Ministero della Difesa (PNRM 2020)
This publication has 71 references indexed in Scilit:
- Evolution of Preclinical Models for Glioblastoma Modelling and Drug ScreeningCurrent Oncology Reports, 2025
- A reference for selecting an appropriate method for generating glioblastoma organoids from the application perspectiveDiscover Oncology, 2024
- A 3D Bioprinted Human Neurovascular Unit Model of Glioblastoma Tumor GrowthAdvanced Healthcare Materials, 2024
- Glioblastoma and cerebral organoids: development and analysis of an in vitro model for glioblastoma migrationMolecular Oncology, 2023
- Glioblastoma, from disease understanding towards optimal cell-based in vitro modelsCellular Oncology, 2022
- Space flight and central nervous system: Friends or enemies? Challenges and opportunities for neuroscience and neuro‐oncologyJournal of Neuroscience Research, 2022
- Simulated microgravity inhibits the viability and migration of glioma via FAK/RhoA/Rock and FAK/Nek2 signalingIn Vitro Cellular & Developmental Biology - Animal, 2019
- Current trends in mouse models of glioblastomaJournal of Neuro-Oncology, 2017
- Modeled microgravity suppressed invasion and migration of human glioblastoma U87 cells through downregulating store-operated calcium entryBiochemical and Biophysical Research Communications, 2015
- Chemoresistance to Temozolomide in Human Glioma Cell Line U251 is Associated with Increased Activity of O 6-methylguanine-DNA Methyltransferase and Can be Overcome by Metronomic Temozolomide RegimenCell Biochemistry and Biophysics, 2011